Co-delivery of docetaxel and gemcitabine by anacardic acid modified self-assembled albumin nanoparticles for effective breast cancer management

Kushwah, Varun; Katiyar, Sameer S.; Dora, Chander Parkash; Agrawal, Ashish Kumar; Gupta, Ramesh C.; Jain, Sanyog

doi:10.1016/j.actbio.2018.03.057

Cited by 89 publications

(34 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The prepared compounds were then subjected to cell viability evaluation against Hela, MCF-7, A-549, and MDA-MB-231 (triple-negative breast cancer cell line) cell lines using the MTT assay [ 26 , 27 , 28 ] at a concentration of 20 mM. The results revealed that only 4 compounds designated with R = phenyl, 3,5-dimethylphenyl, 4-fluorophenyl, and 4-trifluoromethylphenyl exhibited significantly reduced cell viability percentages towards the tested cancer cell lines.…”

Section: Anticancer Activitymentioning

confidence: 99%

Recent Advances in the Synthesis and Biological Activity of 8-Hydroxyquinolines

2020

View full text Add to dashboard Cite

Compounds containing the 8-hydroxyquinoline (8-HQ) 1 nucleus exhibit a wide range of biological activities, including antimicrobial, anticancer, and antifungal effects. The chemistry and biology of this group have attracted the attention of chemists, medicinal chemists, and professionals in health sciences. A number of prescribed drugs incorporate this group, and numerous 8-HQ- based molecules can be used to develop potent lead compounds with good efficacy and low toxicity. This review focusses on the recent advances in the synthesis of 8-HQ derivatives with different pharmacological properties, including anticancer, antiviral, and antibacterial activities. For this purpose, recent relevant references were searched in different known databases and search engines, such as MEDLINE (PubMed), Google Scholar, Science Direct, Scopus, Cochrane, Scientific Information Database (SID), SciFinder, and Institute for Scientific Information (ISI) Web of Knowledge. This review article provides a literature overview of the various synthetic strategies and biological activities of 8-HQ derivatives and covers the recent related literature. Taken together, compounds containing the 8-HQ moiety have huge therapeutic value and can act as potential building blocks for various pharmacologically active scaffolds. In addition, several described compounds in this review could act leads for the development of drugs against numerous diseases including cancer.

show abstract

Section: Anticancer Activitymentioning

confidence: 99%

Recent Advances in the Synthesis and Biological Activity of 8-Hydroxyquinolines

2020

View full text Add to dashboard Cite

show abstract

“…The synthesized compounds were screened for the cytotoxic potential against human cancer cell lines, namely HeLa (cervix cancer cells), MCF‐7 (breast cancer cells), A‐549 (lung cancer cells), MDA‐MB‐231 (triple negative breast cancer cells), via MTT assay, as per our previous protocol, at the concentration of 20 μM . Docetaxel was kept as positive control throughout the study.…”

Section: Resultsmentioning

confidence: 99%

Synthesis and Biological Evaluation of 8‐Hydroxyquinoline‐hydrazones for Anti‐HIV‐1 and Anticancer Potential

et al. 2018

Self Cite

View full text Add to dashboard Cite

8‐Hydroxyquinoline, being one of the privileged scaffolds, is known to possess a wide range of biological activities. 8‐Hydroxyquinoline quinoline has been explored synthetically through functionalization at different positions by different groups in search of medicinally important molecules. Herein, we synthesized twenty‐one (20 a‐20 u) different hydrazones of 8‐hydroxyquinoline at C‐2 position in good yields and characterised by 1H NMR, 13C NMR, HRMS and IR. All the synthesized compounds were evaluated for their anti‐HIV‐1 and anti‐cancer potential through in vitro cell‐based assays. Compound 20 u ((E)‐2‐((2‐(4‐methoxyphenyl)hydrazono)methyl)quinolin‐8‐ol) was found to be the most active against HIV (IC50: 1.88 and 6.27 μM; TI 73.82 and 22.07, against HIV‐1VB59 and HIV‐1UG070 respectively). Compound 20 l ((E)‐2‐((2‐(4‐fluorophenyl)hydrazono)methyl)quinolin‐8‐ol) was identified as the most cytotoxic against four cancer cell lines (IC50: 26.30, 34.19, 38.77 and 34.23 μM against HeLa, MCF‐7, A‐549 and MDA‐MB‐231, respectively) with 2.4, 1.9, 1.6, 1.9‐folds selectivity, respectively over normal cells (IC50 63.75 μM against HEK‐293 normal cells).

show abstract

“…The best efforts were paid to reduce the animal suffering and control their numbers. One week after environmental adaptation, 5 × 10 6 THJ-16T cells were subcutaneously injected into the back, and the tumors formed were passaged to the nude mice for in vivo treatments [28][29][30]. The tumor-bearing animals were randomly divided into four groups as: the control group (without treatment), free resveratrol-treated group [31,32], Pep-1-PEG3.5k-PCL 4k @Res-treated group (30mg kg/day, IP), and docetaxel (5 mg/kg/week, IP) + doxorubicin (5 mg/kg/week, IP) group [33,34].…”

Section: Establishment and Treatment Of Atc Subcutaneous Tumor Modelmentioning

confidence: 99%

“…Ultraviolet spectrophotometer (Evolution 300PC, Thermo Fisher, USA) was used to detect the drug concentration, and the particle size analyzer (Zetasizer Nano S90, UK) was used to evaluate the particle size. When the tumor volumes reached 50-150 mm 3 , Pep-1-PEG 3.5k -PCL 4k @Res in the dose of 30 mg/kg/2 days was administered intraperitoneally for 2 weeks [28][29][30] (Figure 1C). After the treatment, the tumor bearing mice were euthanized.…”

Section: In Vivo Pep-1-peg 35k -Pcl 4k @Res Administrationmentioning

confidence: 99%

Resveratrol and its Nanoparticle suppress Doxorubicin/Docetaxel-resistant anaplastic Thyroid Cancer Cells in vitro and in vivo

Xiong¹,

Lin²,

Nie³

et al. 2021

Nanotheranostics

View full text Add to dashboard Cite

Background: Docetaxel and doxorubicin combination has been widely used in anaplastic thyroid cancer/ATC treatment but often results in serious adverse effects and drug resistance. Resveratrol effectively inhibits ATC cell proliferation in vitro without affecting the corresponding normal cells, while its in vivo anti-ATC effects especially on the ones with docetaxel/doxorubicin-resistance have not been reported due to its low bioavailability. Nanoparticles with sustained-release and cancer-targeting features may overcome this therapeutic bottleneck. Methods: The resveratrol nanoparticles with sustained-release and IL-13Rα2-targeting capacities (Pep-1-PEG3.5k-PCL4k@Res) were prepared to improve the in vivo resveratrol bioavailability. Human THJ-16T ATC cell line was employed to establish nude mice subcutaneous transplantation model. The tumor-bearing mice were divided into four groups as Group-1, without treatment, Group-2, treated by 30 mg/kg free resveratrol, Group-3, treated by 30 mg/kg Pep-1-PEG3.5k-PCL4k@Res and Group-4, treated by 5 mg/kg docetaxel/5 mg/kg doxorubicin combination. TUNEL staining was used to detect the apoptotic cells in the tumor tissues. Docetaxel/doxorubicin resistant xenografts named as THJ-16T/R were isolated and subjected to 2D and 3D culture. The docetaxel/doxorubicin and resveratrol sensitivities of the original THJ-16T and THJ-16T/R cells were analyzed by multiple methods. Results: Docetaxel/doxorubicin and Pep-1-PEG3.5k-PCL4k@Res but not free resveratrol significantly delayed tumor growth (P < 0.01) and caused extensive apoptosis. The mice in docetaxel/doxorubicintreated group suffered from weight loss (> 10%) and 2/3 of them died within 3 times of treatment and the chemotherapy was stop to avoid further animal loss. One week after drug withdrawal, the subcutaneous tumors regrew and the tumor volume increased 55.28% within 14 days. The cells isolated from the regrowing tumors (THJ-16T/R) were successfully cultured under 2D and 3D condition and underwent drug treatments. Compared with THJ-16T, the death rate of docetaxel/doxorubicin-treated THJ-16T/R population was lower (39.3% vs 18.0%), which remained almost unchanged in resveratrol-treated group (45.3% vs 49.3%). Conclusion: Resveratrol sustained-release targeting nanoparticles effectively inhibit in vivo ATC growth. Docetaxel/doxorubicin suppresses ATC xenografts but causes obvious side effects and secondary drug resistance that can be overcome by resveratrol.

show abstract

Co-delivery of docetaxel and gemcitabine by anacardic acid modified self-assembled albumin nanoparticles for effective breast cancer management

Cited by 89 publications

References 39 publications

Recent Advances in the Synthesis and Biological Activity of 8-Hydroxyquinolines

Recent Advances in the Synthesis and Biological Activity of 8-Hydroxyquinolines

Synthesis and Biological Evaluation of 8‐Hydroxyquinoline‐hydrazones for Anti‐HIV‐1 and Anticancer Potential

Resveratrol and its Nanoparticle suppress Doxorubicin/Docetaxel-resistant anaplastic Thyroid Cancer Cells in vitro and in vivo

Contact Info

Product

Resources

About